Abstract
Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2645-2656 |
| Number of pages | 12 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 22 |
| DOIs | |
| State | Published - Aug 1 2019 |
Fingerprint
Keywords
- atypical response
- biomarker
- hyperprogression
- immune checkpoint inhibitor
- immunotherapy
- pseudoprogression
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. / Failing, Jarrett J.; Dudek, Olivia A.; Marin Acevedo, Julian A.; Chirila, Razvan M.; Dong, Haidong M; Markovic, Svetomir Nenad; Dronca, Roxana S.
In: Future Oncology, Vol. 15, No. 22, 01.08.2019, p. 2645-2656.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy
AU - Failing, Jarrett J.
AU - Dudek, Olivia A.
AU - Marin Acevedo, Julian A.
AU - Chirila, Razvan M.
AU - Dong, Haidong M
AU - Markovic, Svetomir Nenad
AU - Dronca, Roxana S
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.
AB - Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.
KW - atypical response
KW - biomarker
KW - hyperprogression
KW - immune checkpoint inhibitor
KW - immunotherapy
KW - pseudoprogression
UR - http://www.scopus.com/inward/record.url?scp=85070791797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070791797&partnerID=8YFLogxK
U2 - 10.2217/fon-2019-0183
DO - 10.2217/fon-2019-0183
M3 - Review article
VL - 15
SP - 2645
EP - 2656
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 22
ER -